Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Eric Jacobsen
Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up of the Pivotal Zuma-1 Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Related publications
Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Outcomes in First Relapsed-Refractory Younger Patients With Mantle Cell Lymphoma: Results From the Mantle-First Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
Cancer
Cancer Research
Oncology
Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma
American Journal of Hematology
Hematology
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Serum Biomarkers Are Associated With Treatment Response in Relapsed Mantle Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison
European Journal of Haematology
Medicine
Hematology
